drugset / Trial / NCT05899907
Efficacy and Safety of Telitacicept in Early SLE
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with early stage of SLE .
Timeline
- Start
- 2022-09-01
- Primary completion
- 2025-03-01
- Completion
- 2025-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |
| Background | AZA | Unknown | — | — |
| Background | CTX | Unknown | — | — |
| Background | CsA | Unknown | — | — |
| Background | HCQ | Unknown | — | — |
| Background | LEF | Unknown | — | — |
| Background | MMF | Unknown | — | — |
| Background | MTX | Unknown | — | — |
| Background | SASP | Unknown | — | — |
| Background | Tacrolimus | Small molecule | — | — |